Literature DB >> 10025920

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups.

F C Arnett1, P Thiagarajan, C Ahn, J D Reveille.   

Abstract

OBJECTIVE: To determine any HLA associations with anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in a large, retrospectively studied, multiethnic group of 262 patients with primary antiphospholipid antibody syndrome (APS), systemic lupus erythematosus (SLE), or another connective tissue disease.
METHODS: Anti-beta2GPI antibodies were detected in sera using an enzyme-linked immunosorbent assay. HLA class II alleles (DRB1, DQA1, and DQB1) were determined by DNA oligotyping.
RESULTS: The HLA-DQB1*0302 (DQ8) allele, typically carried on HLA-DR4 haplotypes, was associated with anti-beta2GPI when compared with both anti-beta2GPI-negative SLE patients and ethnically matched normal controls, especially in Mexican Americans and, to a lesser extent, in whites. Similarly, when ethnic groups were combined, HLA-DQB1*0302, as well as HLA-DQB1*03 alleles overall (DQB1*0301, *0302, and *0303), were strongly correlated with anti-beta2GPI antibodies. The HLA-DR6 (DR13) haplotype DRB1*1302; DQB1*0604/5 was also significantly increased, primarily in blacks. HLA-DR7 was not significantly increased in any of these 3 ethnic groups, and HLA-DR53 (DRB4*0101) was increased in Mexican Americans only.
CONCLUSION: Certain HLA class II haplotypes genetically influence the expression of antibodies to beta2GPI, an important autoimmune response in the APS, but there are variations in HLA associations among different ethnic groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025920     DOI: 10.1002/1529-0131(199902)42:2<268::AID-ANR8>3.0.CO;2-K

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Optimising testing for phospholipid antibodies.

Authors:  M Helbert; S Bodger; J Cavenagh; D D'Cruz; J M Thomas; P MacCallum
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

Review 2.  Ethnic and geographical variation in antiphospholipid (Hughes) syndrome.

Authors:  I Uthman; M Khamashta
Journal:  Ann Rheum Dis       Date:  2005-05-26       Impact factor: 19.103

Review 3.  Genetics of Antiphospholipid Syndrome.

Authors:  Lourdes Ortiz-Fernández; Amr H Sawalha
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

Review 4.  Genetics of antiphospholipid syndrome.

Authors:  Tetsuya Horita; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

5.  A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus.

Authors:  Valeria Orrú; Sophia J Tsai; Blanca Rueda; Edoardo Fiorillo; Stephanie M Stanford; Jhimli Dasgupta; Jaana Hartiala; Lei Zhao; Norberto Ortego-Centeno; Sandra D'Alfonso; Frank C Arnett; Hui Wu; Miguel A Gonzalez-Gay; Betty P Tsao; Bernardo Pons-Estel; Marta E Alarcon-Riquelme; Yantao He; Zhong-Yin Zhang; Hooman Allayee; Xiaojiang S Chen; Javier Martin; Nunzio Bottini
Journal:  Hum Mol Genet       Date:  2008-11-03       Impact factor: 6.150

6.  Graves' disease associated with anticardiolipin antibody positivity and acquired protein S deficiency.

Authors:  Tomohiro Nakayama; Tatsuo Yamamoto; Katsuo Kanmatsuse; Shinichiro Kokubun
Journal:  Rheumatol Int       Date:  2003-02-26       Impact factor: 2.631

7.  Association of HLA-DM polymorphism with the production of antiphospholipid antibodies.

Authors:  M L Sanchez; K Katsumata; T Atsumi; F I Romero; M L Bertolaccini; A Funke; O Amengual; E Kondeatis; R W Vaughan; A Cox; G R V Hughes; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 8.  Pathophysiology of the antiphospholipid antibody syndrome.

Authors:  Rohan Willis; Silvia S Pierangeli
Journal:  Auto Immun Highlights       Date:  2011-03-24

Review 9.  Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome.

Authors:  Marko Radic; Debendra Pattanaik
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.